Legence Corp. (LGN) delivered another emphatic beat-and-raise quarter. GAAP earnings were $1.15 per diluted share, compared with a $0.50 consensus, a 130.0% surprise and a sharp swing from a $(0.02) loss a year ago. Revenue of $1.311 billion topped the $1.24 billion consensus by 5.7% and cleared management's own $1.225-$1.275 billion third-quarter guide. Adjusted EBITDA rose 99% to $177.0 million, well above the $150-$160 million guided range, and margin reached a company-record 13.5%. The central tension is that the profitability story is getting stronger while the growth story is decelerating. That deceleration matters for a stock that had lost nearly half its value since the last report.

The quality of the EPS beat deserves scrutiny. GAAP results were flattered by a $35.3 million non-cash compensation benefit tied to legacy Series A and Restricted Series C interests, compared with an $18.6 million expense a year ago. That swing helps explain why SG&A fell to $70.5 million from $85.9 million despite revenue rising 85%. Net income attributable to Legence was also only about two-thirds of total net income, with $44.3 million going to noncontrolling interests. Adjusted EBITDA is the cleaner gauge, and it still tells a genuinely good story:

• **Installation & Maintenance:** adjusted gross margin improved to 18.0% from 16.6% a year ago and 16.1% in Q2, on better installation and fabrication project margins and scale benefits.
• **Engineering & Consulting:** adjusted gross margin rose to 33.3%.
• **Consolidated adjusted gross margin:** this actually slipped to 20.3% from 21.5%. That reflects mix shift toward the lower-margin I&M segment, not deterioration within either segment.

Beneath the record headlines, growth is cooling. Excluding about $322.7 million of Bowers revenue, organic growth was roughly 40%, down from about 60% in Q2 and 57% in Q1. Engineering & Consulting revenue fell 5.8% year over year. That compares with gains of 6% in Q2 and 14% in Q1, as an NBC project rolled off and education engineering softened. Bookings momentum also eased:

• **Backlog:** the record $5.90 billion backlog (+92%) grew only $229 million sequentially, versus $289 million in Q2.
• **Book-to-bill:** the quarterly ratio was 1.2x versus 1.5x a year ago, and the trailing-twelve-month ratio slipped to 1.3x from 1.4x.
• **Life science and healthcare:** backlog build in this market is lagging revenue, and large hospital projects have not yet been replaced.

Guidance preserved a credible but more measured growth story. The release formally raised 2026 revenue guidance to $4.87-$4.91 billion and adjusted EBITDA to $610-$620 million, up from $4.70-$4.80 billion and $565-$585 million. The call summary framed these figures as implied by year-to-date actuals plus the Q4 guide rather than formally restated, but the numbers agree. This extends a long raise cadence from an initial $3.475-$3.725 billion revenue outlook.

The initial 2027 outlook calls for $5.3-$5.6 billion in revenue and $690-$730 million in adjusted EBITDA, implying only about 8-15% growth. Management attributed this to backlog elongation from larger projects. It also said it did not build Q3's exceptional execution into 2027, which leaves room for upside but also signals caution.

Bears have legitimate ammunition on data centers:

• Roughly 40% of Legence's data center work sits in Northern Virginia, where Loudoun County has paused activity.
• State-level moratorium risk after the midterms came up repeatedly in a more defensive Q&A.

The offsets are tangible:

• **CTI acquisition:** the roughly $100 million purchase of Austin-based Central Texas Industrial Contractors adds semiconductor process-piping exposure and a Texas platform. Less than 10% of Legence's data center work is currently in Texas.
• **New wins:** these include new Bay Area fab work and a large University of California electrification award.
• **Capacity:** fabrication space has expanded to 1.6 million square feet, with more planned.
• **Balance sheet:** net leverage has fallen to 1.2x from 1.8x in Q1, and cash rose to $341 million.

The new $150 million buyback was framed partly as an opportunistic response to valuation.

That valuation context is stark. Shares were $37.09 heading into the report, down 44.1% from the $66.32 opening after the August release. They sat about 41% below the $62.71 200-day moving average and 47% below the $70.17 inter-earnings high set just days after that report. The stock hit a 52-week low of $23.90 on November 5 and had already rebounded 55% from that trough before results. Investor sentiment improved meaningfully, moving from mildly negative (-0.19) to modestly positive (+0.25). Earnings Whispers trend readings are mixed: momentum has turned positive, while the AVWAP trend remains negative, consistent with a stock still repairing heavy damage.

The bottom line is that Legence's operating execution, margin expansion and balance-sheet progress are not in question. The open question is durability. Organic growth has stepped down from roughly 60% to 40%, bookings are moderating, and the 2027 guide implies low-double-digit growth with real regulatory exposure in Northern Virginia. The quarter gives investors more reason to trust the execution, but it does not fully resolve whether the data center cycle can sustain the growth the market once priced in.